From manual to automated: building scalable workflows for autologous CAR-T cell manufacturing

Automation can enhance scalability, consistency, and efficiency in autologous CAR-T cell therapies, but adoption must be carefully phased and aligned with operational goals. This interactive poster illustrates how automation can overcome challenges in autologous CAR-T cell manufacturing, including patient variability, labor-intensive workflows, supply chain issues, and scalability, and includes soundbites from a panel of leading experts – Edwin Stone (CEO, Cellular Origins), Mojtaba Parvizi (Global Fast Trak Director, Cell Therapy, Cytiva), and Matthew Hewitt ( Vice President, CTO Manufacturing Division, Charles River Laboratories).